Summary："Breakthrough $93M Funding Unlocks Revolutionary Treatment for Blindness and Retinal Diseases"BOSTON

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

"Breakthrough $93M Funding Unlocks Revolutionary Treatment for Blindness and Retinal Diseases"

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- Memento Medicines, Inc., a pioneering biotech firm specializing in biologic therapies for retinal diseases, has successfully closed a $93 million Series A financing round. The investment, co-led by Forbion and RA Capital Management, marks a significant milestone in the company's mission to revolutionize the treatment of blindness and retinal disorders.

The substantial funding injection will be channeled into accelerating the development of Memento Medicines' flagship program, a novel biologic therapy designed to address the underlying causes of retinal degeneration. This innovative treatment has shown immense promise in preclinical trials, demonstrating the potential to restore vision in patients suffering from debilitating retinal diseases. With the Series A funds, the company plans to advance its lead candidate into clinical trials, paving the way for a potential breakthrough in the treatment of blindness.

The retinal disease market is characterized by a significant unmet need, with millions of patients worldwide suffering from vision loss due to conditions such as age-related macular degeneration and retinitis pigmentosa. The recent funding success underscores the growing investor confidence in the biotech sector's ability to deliver innovative solutions to these pressing healthcare challenges. As the global population ages, the demand for effective treatments is expected to escalate, presenting a substantial market opportunity for Memento Medicines.

Looking ahead, Memento Medicines is poised to capitalize on the momentum generated by this funding round. The company's robust pipeline and commitment to advancing cutting-edge therapies position it at the forefront of the retinal disease treatment landscape. As the biotech firm progresses towards clinical trials, the potential for its revolutionary treatment to transform patient outcomes is vast.

In conclusion, the $93 million Series A financing round represents a significant validation of Memento Medicines' innovative approach to treating blindness and retinal diseases. As the company continues to push the boundaries of biologic therapies, the prospect of restoring vision to patients worldwide is becoming increasingly tangible. With a strong financial foundation and a clear development roadmap, Memento Medicines is set to make a lasting impact on the retinal disease treatment paradigm.